THE INVESTOR

▶주메뉴 바로가기

▶본문 바로가기

The Korea Herald

Bio & Medicine

May 05, 2022
Lotte trademarks Lotte Biologics in new bio push
November 23, 2020
SkyLabs, Chong Kun Dang team up for heart-monitoring ring

SkyLabs and Chong Kun Dang are initiating sales of ring-type heart monitoring device CART-I for the mass market starting December, SkyLabs announced on Nov. 23. Chong Kun Dang has paid SkyLabs 2.5 billion won ($2.2 million) to SkyLabs for the rights to business-to-consumer sales of the CART-I car...
November 20, 2020
USITC postpones final ruling on Medytox, Daewoong’s BTX trade secret suit

The US’ International Trade Commission on Nov. 20 once again delayed its final ruling on a trade secret suit between Korean companies Medytox and Daewoong involving a botulinum toxin strain. The ITC did not elaborate on the reason for the postponement, but the agency‘s website indicates that t...
November 12, 2020
Sartorius to invest $100m in Korean bio cluster Songdo

Sartorius, a German life sciences company with 170 years of history, announced on Nov. 12 that it will invest $100 million in Korea’s bio cluster of Songdo in Incheon to build a manufacturing facility for biologics plant parts. Sartorius’ decision is largely attributable to Korea’s leading bio...
October 29, 2020
Samsung Biologics opens 1st overseas CDO at heart of San Francisco biotech hub

Biopharmaceutical firm Samsung Biologics unveiled its first research and development center for contract development in the biotechnology hub in southern San Francisco on Thursday. The contract development organization is designed to serve clients -- mostly biopharmaceutical firms there -- to offe...
August 07, 2020
Enzychem Lifesciences’ COVID-19 drug proceeds to phase 2 trial

Enzychem Lifesciences’ COVID-19 treatment candidate EC-18 was granted by the US’ Food and Drug Administration to carry out phase 2 clinical trial on confirmed patients, the company said on August 7. In this phase 2 clinical trial, Enzychem Lifesciences will confirm the therapeutic effects of EC...
July 29, 2020
GC’s potential blazes through pandemic crisis

GC Pharma on July 29 sought the Drug Ministry’s approval to carry out a phase 2 clinical trials of its plasma-derived COVID-19 treatment. The company plans to conduct tests of its GC5131A on 60 patients at Samsung Medical Center, Asan Medical Center, Chung-Ang University Hospital, Korea Universi...
July 27, 2020
Vaccine developer SK Bioscience plans 2021 IPO

SK Group is pushing for another initial public offering of its health care affiliate SK Bioscience, just a month after SK Biopharmaceuticals’ record-breaking stock market entry last month. SK Bioscience, a vaccine developer that was spun-off from SK Chemical in July 2018, will reportedly file fo...
July 24, 2020
Celltrion launches human clinical trials of potential COVID-19 antibody treatment

South Korean biopharma giant Celltrion said on July 24 it has launched phase 1 clinical trials of a potential antiviral antibody treatment for COVID-19 patients. The clinical study follows promising preclinical results for the virus treatment candidate and has received approval from the Korean M...
July 21, 2020
COVID-19 test kit company Seegene soars to Kosdaq No. 2

Seegene, a Korean diagnostics company acclaimed for having preemptively developed COVID-19 test kits before the pandemic even reached Korea, has since risen to the second rank on the Kosdaq bourse. The ongoing coronavirus threat has shifted the market positions of companies across industries, wit...
June 30, 2020
Chunlab launches health care services centering on feces analyzation

We know this by many names. Poo, feces, stool, turd, excrement. ... The list can grow endless if imaginative children join in. But scatology is not a matter to be lightly regarded, as “gut feelings” take on a literal meaning in health care. Chunlab, a microbiome research firm, on Tuesday launch...
June 24, 2020
SK Biopharmaceuticals set to make historic IPO

SK Biopharmaceuticals, a drug company researching and developing novel medicines for central nervous system disorders, is set to make a record-breaking initial public offering. On June 24, the second and final day of the company’s subscription-open for individual investors, the proof of means th...
June 22, 2020
SK Biopharm likely to join Kospi 200 in September: analysts

South Korean drug developer SK Biopharmaceuticals is likely to get an early admission to join the Kospi 200 -- a basket of top 200 blue-chip stocks of the nation’s benchmark index Kospi -- possibly only two months after its planned market debut in July, according to local analysts on June 22. If...
June 03, 2020
Celltrion aims to commercialize insulin pen by 2025

Biologics drug developer Celltrion said Wednesday it will accelerate its insulin pen biosimilar development along with medical device manufacturer Poonglim Pharmatech. Celltrion will begin developing the insulin biosimilar this year with aims to commercially launch the product in 2025. Global i...
May 22, 2020
Samsung Biologics bags CMO deals worth W468b

Samsung Biologics has bagged two contract manufacturing deals worth 468 billion won ($378 million) combined, according to its regulatory filing on May 22. The total value of the latest deals is equal to two-thirds of the company’s revenue for last year at 701 billion won. According to the biop...

1 2 3 4 5 6 7 8 9 10

EDITOR'S PICKS

Herald Corporation |
CEO : Jeon Chang-hyeop |
Huam-ro 4-gil 10, Yongsan-gu, Seoul, Korea |
Title : The Investor |
Date of registration : 2015.04.28

Publisher. Editor : Jeon Chang-hyeop |
Chief Privacy Officer & Juvenile Protection Manager : Kim Young-won |
T +82-2-727-0114

FAMILY SITE GO

Company Registration No. 104-81-06004 |
Mail-Order Business Registration 2016 - Seoul Yongsan - 00590 |
Business info |
Gov’t registration No. Seoul 아04099